Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 26.
doi: 10.1515/cclm-2024-0477. Online ahead of print.

IVDCheckR - simplifying documentation for laboratory developed tests according to IVDR requirements by introducing a new digital tool

Yadwinder Kaur  1 , Daniel Rosenkranz  1 , Anna Bloemer  1 , Ozan Aykurt  2   3 , Gunnar Brandhorst  1 , Folker Spitzenberger  2   3 , Astrid Petersmann  1   4
Affiliations

IVDCheckR - simplifying documentation for laboratory developed tests according to IVDR requirements by introducing a new digital tool

Yadwinder Kaur et al. Clin Chem Lab Med. .

Abstract

Objectives: A recent challenge for clinical laboratories is the lack of clear guidelines for handling significant modifications of CE-marked assays. The modifications may involve, for example, extending measurement intervals, changing dilution procedures or using non-validated sample materials. The challenge arises due to the amended Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), which is now poised for implementation, despite the extended transition periods. The IVDR application imposes challenges not only for diagnostic companies but also for clinical laboratories when using laboratory developed tests (LDTs), often referred to as in-house assays. In this context, a coherent and meticulously structured LDT documentation is highly beneficial. While laboratories are obliged to meet the IVDR requirements, the absence of a streamlined framework or guideline hampers the ability to gain a comprehensive overview on the requirements and possible options for their fulfilment.

Methods: To address this issue, we introduce a web based digital tool powered by an R Shiny web application. This tool facilitates a seamless implementation of IVDR requirements for LDTs across diverse laboratory environments in terms of their transparency and validity. Our approach focuses on adequate handling of significant modifications of CE-marked in vitro diagnostic medical devices (IVD).

Results: IVDRCheckR is an open-source tool that is easily accessible and free from system dependencies. The tool promotes a seamless process and a guide to enhance transparency, reliability, and validity of laboratory examination results based on LDTs. Additionally, the tool further provides modules for evaluating quality control data and quantitative method comparison data.

Conclusions: Our Shiny web application-based platform is a digitised, user-friendly tool that simplifies the documentation for LDTs according to IVDR requirements with special emphasis on solutions for handling modifications to CE-marked assays.

Keywords: Shiny; amended Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR); in-house IVD; in vitro diagnostics; laboratory developed test (LDT); significant modification.

PubMed Disclaimer

References

    1. EU Regulations. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU [Online]; 2017. Available from: https://eur-lex.europa.eu/eli/reg/2017/746/oj .
    1. EU Regulations. Regulation (EU) 2022/112 of the European Parliament and of the Council of 25 January 2022 amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices [Online]; 2022. Available from: https://eur-lex.europa.eu/eli/reg/2022/112/oj .
    1. Spitzenberger, F, Patel, J, Gebuhr, I, Kruttwig, K, Safi, A, Meisel, C. Laboratory-developed tests: design of a regulatory strategy in compliance with the international state-of-the-art and the regulation (EU) 2017/746 (EU IVDR [in vitro diagnostic medical device regulation]). Ther Innov Regul Sci 2022;56:47–64. https://doi.org/10.1007/s43441-021-00323-7 . - DOI
    1. Carpenter, RE, Tamrakar, VK, Almas, S, Brown, E, Sharma, R. COVIDSeq as laboratory developed test (LDT) for diagnosis of SARS-CoV-2 variants of concern (VOC). Arch Clin Biomed Res 2022;6:954–70. https://doi.org/10.26502/acbr.50170309 . - DOI
    1. Lieberman, JA, Pepper, G, Naccache, SN, Huang, ML, Jerome, KR, Greninger, AL. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 2020;58:e00821–20. https://doi.org/10.1128/jcm.00821-20 . - DOI

LinkOut - more resources